PIM激酶抑制可逆转前列腺癌放化疗抵抗
研究通过细胞实验和小鼠移植瘤模型探讨PIM抑制能否克服前列腺癌对放疗和多西他赛的抵抗。PIM抑制减少放疗诱导的DNA损伤修复并降低细胞增殖与存活,在小鼠中增强放疗和多西他赛缩小激素依赖及非依赖移植瘤的疗效。作者认为数据为在临床试验中测试PIM抑制剂联合标准治疗高危局限或转移性前列腺癌提供了有力依据。
要点
- PIM抑制降低放疗诱导的DNA损伤修复并减少前列腺癌细胞增殖与存活。
- 小鼠中PIM抑制增强放疗和多西他赛缩小激素依赖和非依赖移植瘤的疗效。
- 作者认为数据支持在临床试验中测试PIM抑制剂联合标准治疗前列腺癌。
核心结论
- PIM抑制在多种前列腺癌模型中克服对多西他赛和放疗的治疗抵抗。
- 作者认为数据为在临床试验中测试PIM抑制剂联合标准治疗治疗抵抗性高危局限或转移性前列腺癌提供了有力依据。
研究设计与样本
- 研究在前列腺癌细胞系中通过磷酸化H2AX和集落形成实验检测PIM抑制。
- 在正常和去势小鼠前列腺肿瘤移植瘤模型中,每日口服PIM抑制剂联合或不联合分次放疗或多西他赛并监测肿瘤生长。
- 放疗方案为30 Gy分15次,模拟临床常规每日治疗3周。
主要发现
- PIM抑制减少放疗诱导的DNA损伤修复并降低细胞增殖与存活。
- 小鼠中PIM抑制增强放疗和多西他赛缩小激素依赖及非依赖移植瘤的疗效。
- RNA-Seq分析显示PIM抑制导致移植瘤基因表达改变,包括核糖体通路下调和心肌细胞信号通路上调。
- 免疫染色显示包括COX-2和MDM2在内的多种蛋白因PIM抑制而改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PIM kinases are associated with treatment resistance and poor prognosis in prostate cancer through roles in DNA damage response, cellular metabolism, proliferation, and survival. We hypothesized PIM inhibition addresses treatment resistance to radiotherapy and docetaxel in prostate cancer. METHODS: PIM inhibition in prostate cancer cell lines was examined by phosphorylated H2AX and colony formations assays. In normal and castrated mice with prostate tumor xenografts, tumor growth was monitored with daily oral PIM inhibition +/- fractionated radiotherapy (RT) or docetaxel. Radiotherapy was given 30 Gy in 15 treatments, mimicking clinical conventional daily treatment over 3 weeks in a translational murine model system. RESULTS: PIM inhibition decreased radiotherapy-induced DNA-damage repair and decreased cell proliferation and survival. In mice, PIM inhibition increased the efficacy of both radiation and docetaxel to reduce tumor size in hormone-dependent and -independent xenografts. Xenografts showed altered gene expression changes, including downregulation of ribosomal pathways and upregulation of cardiomyocyte signaling pathways, due to PIM inhibition as analyzed by RNA-Seq. Immunostaining of multiple proteins, including COX-2 and MDM2, was altered by PIM inhibition. CONCLUSIONS: PIM inhibition addresses treatment resistance to docetaxel and radiotherapy in multiple prostate cancer models. Our data provide a strong rationale for testing PIM inhibitors in combination with standard therapies for treatment-resistant high-risk localized or metastatic prostate cancer in clinical trials.
引用
- Rajkumar-Calkins A, Sagar V, Wang J, et al. PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer. Radiother Oncol. 2025. PMID: 39978680. doi:10.1016/j.radonc.2025.110794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。